Abstract:Abstract Magnesium (Mg2+) is essential for energy metabolism, muscle contraction, and neurotransmission. As part of the Mg-ATP complex, it is involved in over 600 enzymatic reactions. Serum Mg2+ levels are tightly regulated between 0.7 mmol/L and 1.1 mmol/L by interplay of intestinal absorption and renal excretion. In the small intestine, Mg2+ is absorbed paracellularly via claudin-2, and -12. In the colon, transcellular absorption of Mg2+ is facilitated by TRPM6/7 and CNNM4. In the kidney, the proximal tubule reabsorbs only 20% of the filtered Mg2+. The majority of the filtered Mg2+ is reabsorbed in the thick ascending limb (TAL), where the lumen-positive transepithelial voltage drives paracellular transport via claudin-16/-19. Fine-tuning of Mg2+ reabsorption is achieved in the distal convoluted tubule (DCT). Here, TRPM6/7 tetramers facilitate apical Mg2+ uptake, which is hormonally regulated by insulin and EGF. Basolateral Mg2+ extrusion is Na+ dependent and achieved by CNNM2 and/or SLC41A3. Hypomagnesemia (serum Mg2+ < 0.7 mmol/L) develops when intestinal and/or renal Mg2+ (re)absorption is disturbed. Common causes include alcoholism, type 2 diabetes mellitus, and the use of pharmacological drugs, such as proton-pump inhibitors (PPIs), calcineurin inhibitors (CNIs) and thiazide diuretics. Over the last decade, research on rare genetic and acquired Mg2+ disorders have identified Mg2+ channel and transporter activity, DCT length, mitochondrial function, and autoimmunity as mechanisms explaining hypomagnesemia. Classically, treatment of hypomagnesemia depended on oral or intravenous Mg2+ supplementation. Recently, prebiotic dietary fibers and SGLT2 inhibitors have been proposed as promising new therapeutic pathways to treat hypomagnesemia.

Sodium/Glucose Cotransporter 2 Inhibitors and Magnesium Homeostasis

[Magnesium in critical care and anesthesiology]

Genetics of Magnesium Disorders

Magnesium Biology

Higher serum magnesium levels associated with the use of sodium – glucose cotransporter 2 ( SGLT 2 ) inhibitors among type 2 diabetes patients : a meta-analysis of randomized controlled trials

Elevated Serum Magnesium Associated with SGLT2 Inhibitor Use in Type 2 Diabetes Patients: a Meta-Analysis of Randomised Controlled Trials

Effects of Magnesium Deficiency on Mechanisms of Insulin Resistance in Type 2 Diabetes: Focusing on the Processes of Insulin Secretion and Signaling

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Nondiabetic Patients with Chronic Kidney Disease: A Review of Recent Evidence

Magnesium in Obesity, Metabolic Syndrome, and Type 2 Diabetes

The interplay between sodium/glucose cotransporter type 2 and mitochondrial ionic environment

Improving diagnosis and treatment of hypomagnesemia

Molecular determinants of magnesium homeostasis: insights from human disease

Magnesium Disorders: Core Curriculum 2024

Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey

Sodium Glucose Cotransporter-2 Inhibitors in Non-Diabetic Kidney Disease: Evidence in Experimental Models

The role of magnesium in pancreatic beta-cell function and homeostasis

Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition

Magnesium and Human Health: Perspectives and Research Directions

SGLT2 inhibitors increase low serum magnesium levels in patients with chronic kidney disease immediately after treatment

Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?